Cargando…

Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

BACKGROUND: The Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study the clinical validity of the CAPRA score, and, second, to assess its c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorent, Marine, Maalmi, Haïfa, Tessier, Philippe, Supiot, Stéphane, Dantan, Etienne, Foucher, Yohann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323757/
https://www.ncbi.nlm.nih.gov/pubmed/30616621
http://dx.doi.org/10.1186/s12911-018-0727-2
_version_ 1783385830512918528
author Lorent, Marine
Maalmi, Haïfa
Tessier, Philippe
Supiot, Stéphane
Dantan, Etienne
Foucher, Yohann
author_facet Lorent, Marine
Maalmi, Haïfa
Tessier, Philippe
Supiot, Stéphane
Dantan, Etienne
Foucher, Yohann
author_sort Lorent, Marine
collection PubMed
description BACKGROUND: The Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study the clinical validity of the CAPRA score, and, second, to assess its clinical utility for stratified medicine from an original patient-centered approach. METHODS: We proposed a meta-analysis based on a literature search using MEDLINE. Observed and predicted biochemical-recurrence-free survivals were compared to assess the calibration of the CAPRA score. Discriminative capacities were evaluated by estimating the summary time-dependent ROC curve. The clinical utility of the CAPRA score was evaluated according to the following stratified decisions: active monitoring for low-risk patients, prostatectomy for intermediate-risk patients, or radio-hormonal therapy for high risk patients. For this purpose, we assessed CAPRA’s clinical utility in terms of its ability to maximize time-dependent utility functions (i.e. Quality-Adjusted Life-Years – QALYs). RESULTS: We identified 683 manuscripts and finally retained 9 studies. We reported good discriminative capacities with an area under the SROCt curve at 0.73 [95%CI from 0.67 to 0.79], while graphical calibration seemed acceptable. Nevertheless, we also described that the CAPRA score was unable to discriminate between the three medical alternatives, i.e. it did not allow an increase in the number of life years in perfect health (QALYs) of patients with prostate cancer. CONCLUSIONS: We confirmed the prognostic capacities of the CAPRA score. In contrast, we were not able to demonstrate its clinical usefulness for stratified medicine from a patient-centered perspective. Our results also highlighted the confusion between clinical validity and utility. This distinction should be better considered in order to develop predictive tools useful in practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12911-018-0727-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6323757
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63237572019-01-10 Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA) Lorent, Marine Maalmi, Haïfa Tessier, Philippe Supiot, Stéphane Dantan, Etienne Foucher, Yohann BMC Med Inform Decis Mak Research Article BACKGROUND: The Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study the clinical validity of the CAPRA score, and, second, to assess its clinical utility for stratified medicine from an original patient-centered approach. METHODS: We proposed a meta-analysis based on a literature search using MEDLINE. Observed and predicted biochemical-recurrence-free survivals were compared to assess the calibration of the CAPRA score. Discriminative capacities were evaluated by estimating the summary time-dependent ROC curve. The clinical utility of the CAPRA score was evaluated according to the following stratified decisions: active monitoring for low-risk patients, prostatectomy for intermediate-risk patients, or radio-hormonal therapy for high risk patients. For this purpose, we assessed CAPRA’s clinical utility in terms of its ability to maximize time-dependent utility functions (i.e. Quality-Adjusted Life-Years – QALYs). RESULTS: We identified 683 manuscripts and finally retained 9 studies. We reported good discriminative capacities with an area under the SROCt curve at 0.73 [95%CI from 0.67 to 0.79], while graphical calibration seemed acceptable. Nevertheless, we also described that the CAPRA score was unable to discriminate between the three medical alternatives, i.e. it did not allow an increase in the number of life years in perfect health (QALYs) of patients with prostate cancer. CONCLUSIONS: We confirmed the prognostic capacities of the CAPRA score. In contrast, we were not able to demonstrate its clinical usefulness for stratified medicine from a patient-centered perspective. Our results also highlighted the confusion between clinical validity and utility. This distinction should be better considered in order to develop predictive tools useful in practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12911-018-0727-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-07 /pmc/articles/PMC6323757/ /pubmed/30616621 http://dx.doi.org/10.1186/s12911-018-0727-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lorent, Marine
Maalmi, Haïfa
Tessier, Philippe
Supiot, Stéphane
Dantan, Etienne
Foucher, Yohann
Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title_full Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title_fullStr Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title_full_unstemmed Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title_short Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)
title_sort meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the cancer of the prostate risk assessment (capra)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323757/
https://www.ncbi.nlm.nih.gov/pubmed/30616621
http://dx.doi.org/10.1186/s12911-018-0727-2
work_keys_str_mv AT lorentmarine metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra
AT maalmihaifa metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra
AT tessierphilippe metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra
AT supiotstephane metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra
AT dantanetienne metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra
AT foucheryohann metaanalysisofpredictivemodelstoassesstheclinicalvalidityandutilityforpatientcenteredmedicaldecisionmakingapplicationtothecanceroftheprostateriskassessmentcapra